Clinical trial · Interventional
Radiochemotherapy in Elderly Patients With Oesophagus Cancer
Phase II of Radiochemotherapy in Elderly Patients With Oesophagus Cancer
NCT02879227CI-TRIAL-00023643ChronoscompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase II study of radiochemotherapy for elderly patients with oesophagus cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagus Cancer | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm Cisplatin
- description
- Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
- interventionNames
- Drug: Cisplatin
- type
- EXPERIMENTAL
- label
- Arm Oxaliplatin
- description
- Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
- interventionNames
- Drug: Oxaliplatin
Primary outcomes (1)
- measure
- Feasibility of treatment: Number of patients with completed treatment
- timeFrame
- 6 weeks after end of the radiochemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * patients aged 75 or more with oesophagus cancer (squamous or adenocarcinoma), fit to treat Exclusion Criteria: * previous radiotherapy * no fit to treat
References
Publications (2)
- BACKGROUNDServagi-Vernat S, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Maingon P, Mercier M, Bosset JF. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study. Drugs Aging. 2009;26(3):255-62. doi: 10.2165/00002512-200926030-00006. PMID 19358620
- RESULTServagi-Vernat S, Crehange G, Roullet B, Guimas V, Maingon P, Puyraveau M, Bosset JF. Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and Older with Esophageal Cancer. Drugs Aging. 2015 Jun;32(6):487-93. doi: 10.1007/s40266-015-0275-8. PMID 26038198